Cognitive decline and brain volume loss as signatures of cerebral amyloid-β peptide deposition identified with Pittsburgh compound B: Cognitive decline associated with Aβ deposition

Archives of Neurology

Volumn 66, Issue 12, 2009, Pages 1476-1481

  Storandt, Martha ^a   Mintun, Mark A ^b   Head, Denise ^a,b   Morris, John C ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 11; CONTRAST MEDIUM; PITTSBURGH COMPUND B; UNCLASSIFIED DRUG;

AGED; ARTICLE; BRAIN CORTEX; BRAIN SIZE; CINGULATE GYRUS; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL DETERIORATION; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RATING SCALE; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANILINE COMPOUNDS; BRAIN; CARBON RADIOISOTOPES; CEREBRAL CORTEX; COGNITION DISORDERS; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; ORGAN SIZE; PEPTIDE FRAGMENTS; PROTEIN BINDING; THIAZOLES;

EID: 73549106106     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.272     Document Type: Article

References (43)

1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.
2. Lockhart A, Lamb JR, Osredkar T, et al. PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis. Brain. 2007;130(pt 10):2607-2615.
3. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008;65(10):1304-1309.
4. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in-vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(pt 6):1630-1645.
5. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45(3):358-368.
6. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837-1844.
7. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026-1036.
8. Mintun MA, LaRossa GN, Sheline YI, et al. [11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.
9. Rowe CC, Ng S, Ackermann U, et al. Imaging β-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-1725.
10. Pike KE, Savage G, Villemagne VL, et al. β-amyloid imaging and memory in nondemented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130(Pt 11):2837-2844.
11. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131(pt 3):665-680.
12. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509-1517.
13. Mormino EC, Kluth JT, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated β-amyloid deposition in elderly subjects. Brain. 2009;132(pt 5):1310-1323.
14. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497-510.
15. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res. 1975;12(3):189-198.
17. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55(3):326-335.
18. Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathological outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67(3):467-473.
19. Johnson DK, Storandt M, Morris JC, Langford ZD, Galvin JE. Cognitive profiles in dementia: Alzheimer disease vs healthy brain aging. Neurology. 2008;71(22):1783-1789.
20. Wechsler D, Stone CP. Manual: Wechsler Memory Scale. New York, NY: Psychological Corp; 1973.
21. Wechsler D. Manual: Wechsler Adult Intelligence Scale. New York, NY: Psychological Corp; 1955.
22. Goodglass H, Kaplan E. The Assessment of Aphasia and Related Disorders. 2nd ed. Philadelphia, PA: Lea & Febiger, 1983.
23. Benton AL. The Revised Visual Retention Test: Clinical and Experimental Applications. New York, NY: Psychological Corp; 1963.
24. Armitage SG. An analysis of certain psychological tests used in the evaluation of brain injury. Psych Monogr. 1946;60:1-48.
25. Thurstone LL, Thurstone LG. Examiner Manual for the SRA Primary Mental Abilities Test. Chicago, IL: Science Research Associates Inc; 1949.
26. Mathis CA, Wang Y, Holt DP, Huang G-F, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13):2740-2754.
27. Accorsi R, Adam LE, Werner ME, Karp JS. Optimization of a fully 3D single scatter simulation algorithm for 3D PET. Phys Med Biol. 2004;49(12):2577-2598.
28. Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlasbased head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004;23(2):724-738.
29. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. Stuttgart, Germany: Thieme Medical Publishers Inc; 1988.
30. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-) cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10(5):740-747.
31. Logan J, Fowler JS, Volkow ND, Wang G-J, Ding Y-S, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834-840.
32. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984;15(3):217-227.
33. 42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349.
34. Head D, Snyder AZ, Girton LE, Morris JC, Buckner RL. Frontal-hippocampal double dissociation between normal aging and Alzheimer's disease. Cereb Cortex. 2005;15(6):732-739.
35. Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968-980.
36. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341-355.
37. Han X, Jovicich J, Salat DH, et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage. 2006;32(1):180-194.
38. Jovicich J, Czanner S, Han X, et al. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage. 2009;46(1):177-192.
39. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
40. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA. 1989;262(18):2551-2556.
41. Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the cardiovascular health study. J Am Geriatr Soc. 2004;52(2):195-204.
42. Frisoni G, Testa C, Zorzan A, et al. Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry. J Neurol Neurosurg Psychiatry. 2002;73(6):657-664.
43. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65(2):176-183.